PMID- 27749218
OWN - NLM
STAT- MEDLINE
DCOM- 20170620
LR  - 20220409
IS  - 0392-856X (Print)
IS  - 0392-856X (Linking)
VI  - 34
IP  - 6
DP  - 2016 Nov-Dec
TI  - Serum calprotectin is a biomarker of carotid atherosclerosis in patients with 
      primary Sjogren's syndrome.
PG  - 1006-1012
AB  - OBJECTIVES: We aimed to identify the association of carotid atherosclerosis with 
      the traditional risk factors, disease features, cytokine profile, and 
      calprotectin in patients with primary Sjogren's syndrome (pSS). METHODS: 63 
      primary pSS patients and 63 age- and sex-matched healthy controls underwent 
      carotid ultrasound, clinical and laboratory examination. The presence of carotid 
      plaques was taken as carotid atherosclerosis. The covariates of carotid 
      atherosclerosis were identified in univariate and multivariate regressions. 
      RESULTS: Patients with pSS had higher prevalence of carotid atherosclerosis (13% 
      vs. 2%, p<0.05) and higher serum levels of calprotectin, tumour necrosis factor 
      receptor 2 (TNF-R2), hepatocyte growth factor (HGF), and monocyte chemoattractant 
      protein-1 (MCP-1) than controls. Sex, menopause, and the prevalence of 
      traditional cardiovascular did not differ between groups (all p>0.05). In 
      univariate analyses, serum calprotectin, most traditional cardiovascular (age, 
      male sex, metabolic syndrome, hypertension, hypertriglyceridaemia, and serum 
      creatinine), and some disease-associated risk factors (glucocorticoid or saliva 
      substitute use, constitutional domain of Eular-Sjogren's syndrome disease 
      activity index - EULAR) were associated with a higher risk for plaque. In a 
      multivariate analysis, having pSS and higher serum calprotectin were associated 
      with carotid atherosclerosis independent of traditional risk factors. 
      CONCLUSIONS: pSS have a higher prevalence of carotid atherosclerosis, which is 
      associated with higher serum calprotectin level independent of traditional 
      cardiovascular risk factors. Our findings suggest calprotectin as a biomarker of 
      subclinical atherosclerosis in pSS.
FAU - Balarini, Gabriela M
AU  - Balarini GM
AD  - The Center of Health Science, Federal University of Espirito Santo (UFES), 
      Brazil.
FAU - Zandonade, Eliana
AU  - Zandonade E
AD  - Department of Statistics, Federal University of Espirito Santo (UFES), Brazil.
FAU - Tanure, Leandro
AU  - Tanure L
AD  - Department of Locomotor System, Federal University of Minas Gerais, Brazil.
FAU - Ferreira, Gilda A
AU  - Ferreira GA
AD  - Department of Locomotor System, Federal University of Minas Gerais, Brazil.
FAU - Sardenberg, Wildner M
AU  - Sardenberg WM
AD  - The Center of Health Science, Federal University of Espirito Santo (UFES), 
      Brazil.
FAU - Serrano, Erica V
AU  - Serrano EV
AD  - The Center of Health Science, Federal University of Espirito Santo (UFES), 
      Brazil.
FAU - Dias, Cleia C
AU  - Dias CC
AD  - The Center of Health Science, Federal University of Espirito Santo (UFES), 
      Brazil.
FAU - Navarro, Tulio P
AU  - Navarro TP
AD  - Department of Locomotor System, Federal University of Minas Gerais, Brazil.
FAU - Nordal, Hilde H
AU  - Nordal HH
AD  - Broegelmann Research Laboratory, University of Bergen, Norway.
FAU - Mydel, Piotr M
AU  - Mydel PM
AD  - Broegelmann Research Laboratory; and Department of Clinical Science, University 
      of Bergen, Norway.
FAU - Brun, Johan G
AU  - Brun JG
AD  - Broegelmann Research Laboratory; and Department of Clinical Science, University 
      of Bergen, Norway.
FAU - Brokstad, Karl A
AU  - Brokstad KA
AD  - Broegelmann Research Laboratory, University of Bergen, Norway.
FAU - Gerdts, Eva
AU  - Gerdts E
AD  - Department of Clinical Science, University of Bergen, Norway.
FAU - Jonsson, Roland
AU  - Jonsson R
AD  - Broegelmann Research Laboratory; and Department of Clinical Science, University 
      of Bergen, Norway.
FAU - Valim, Valeria
AU  - Valim V
AD  - The Center of Health Science, Federal University of Espirito Santo (UFES), 
      Brazil; and Broegelmann Research Laboratory, University of Bergen, Norway. 
      val.valim@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20160908
PL  - Italy
TA  - Clin Exp Rheumatol
JT  - Clinical and experimental rheumatology
JID - 8308521
RN  - 0 (Biomarkers)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Leukocyte L1 Antigen Complex)
RN  - 0 (Receptors, Tumor Necrosis Factor, Type II)
RN  - 67256-21-7 (Hepatocyte Growth Factor)
SB  - IM
MH  - Adult
MH  - Atherosclerosis/blood/complications/*diagnosis
MH  - Biomarkers/blood
MH  - Carotid Artery Diseases/blood/complications/*diagnosis
MH  - Chemokine CCL2/blood
MH  - Female
MH  - Hepatocyte Growth Factor/blood
MH  - Humans
MH  - Leukocyte L1 Antigen Complex/*blood
MH  - Male
MH  - Middle Aged
MH  - Receptors, Tumor Necrosis Factor, Type II/blood
MH  - Severity of Illness Index
MH  - Sjogren's Syndrome/blood/*complications
EDAT- 2016/10/18 06:00
MHDA- 2017/06/21 06:00
CRDT- 2016/10/18 06:00
PHST- 2015/12/05 00:00 [received]
PHST- 2016/04/04 00:00 [accepted]
PHST- 2016/10/18 06:00 [pubmed]
PHST- 2017/06/21 06:00 [medline]
PHST- 2016/10/18 06:00 [entrez]
AID - 10210 [pii]
PST - ppublish
SO  - Clin Exp Rheumatol. 2016 Nov-Dec;34(6):1006-1012. Epub 2016 Sep 8.